[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 28 of about 28
1. Lashkari A, Chow WA, Valdes F, Leong L, Phan V, Twardowski P, Kapoor N, Molina A, Al-Kadhimi Z, Frankel P, Somlo G: Tandem high-dose chemotherapy followed by autologous transplantation in patients with locally advanced or metastatic sarcoma. Anticancer Res; 2009 Aug;29(8):3281-8
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tandem high-dose chemotherapy followed by autologous transplantation in patients with locally advanced or metastatic sarcoma.
  • BACKGROUND: Patients with locally advanced or metastatic/recurrent soft tissue and Ewing's sarcoma (EWS) have few treatment options.
  • The purpose of our phase II study was to assess the feasibility, safety and efficacy of tandem high-dose chemotherapy (HDCT) followed by autologous stem cell transplantation (ASCT) in such patients.
  • The first cycle of HDCT consisted of doxorubicin (150 mg/m(2)) and ifosfamide (14 g/m(2)) mixed with mesna (14 g/m(2)), while the second cycle consisted of melphalan (150 mg/m(2)) and cisplatin (200 mg/m(2)).
  • No treatment-related mortality occurred and grade 3 or 4 toxicity was clinically tolerable.
  • Out of the four patients still alive, two had EWS and measurable disease at the time of ASCT and achieved a complete remission, remaining progression free 126 and 155 months after ASCT.
  • CONCLUSION: Our study demonstrates the feasibility and safety of tandem HDCT in patients with high-risk or metastatic/recurrent sarcoma, with some patients achieving long-term PFS and OS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / therapy. Hematopoietic Stem Cell Transplantation. Neoplasm Recurrence, Local / therapy. Sarcoma / therapy
  • [MeSH-minor] Adult. Cisplatin / administration & dosage. Combined Modality Therapy. Disease Progression. Doxorubicin / administration & dosage. Feasibility Studies. Female. Humans. Ifosfamide / administration & dosage. Immunoenzyme Techniques. Male. Melphalan / administration & dosage. Mesna / administration & dosage. Neoplasm Staging. Neuroectodermal Tumors, Primitive, Peripheral / pathology. Neuroectodermal Tumors, Primitive, Peripheral / therapy. Osteosarcoma / pathology. Osteosarcoma / therapy. Prognosis. Prospective Studies. Protective Agents / administration & dosage. Remission Induction. Rhabdomyosarcoma / pathology. Rhabdomyosarcoma / therapy. Safety. Sarcoma, Ewing / pathology. Sarcoma, Ewing / therapy. Survival Rate. Transplantation, Autologous. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19661346.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Protective Agents; 80168379AG / Doxorubicin; NR7O1405Q9 / Mesna; Q20Q21Q62J / Cisplatin; Q41OR9510P / Melphalan; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


2. Okada K, Hasegawa T, Tateishi U, Endo M, Itoi E: Dedifferentiated chondrosarcoma with telangiectatic osteosarcoma-like features. J Clin Pathol; 2006 Nov;59(11):1200-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dedifferentiated chondrosarcoma with telangiectatic osteosarcoma-like features.
  • A wide excision of the left proximal femur with a replacement by endoprosthesis was carried out in February 2001 after treatment with methotrexate and 20 Gy radiation therapy.
  • Pathological examination of the surgical specimen showed a focus of low-grade chondrosarcoma and the coexistence of telangiectatic osteosarcoma-like features.
  • The patient was diagnosed with dedifferentiated chondrosarcoma with telangiectatic osteosarcoma-like features.
  • Lung metastasis appeared in July 2001 despite an adjuvant chemotherapy including methotrexate, cis-platinum and doxorubicin.
  • Establishing a definitive diagnosis of dedifferentiated chondrosarcoma may be difficult with limited small biopsy specimens.
  • [MeSH-major] Bone Neoplasms / diagnosis. Chondrosarcoma / diagnosis. Mixed Tumor, Malignant / diagnosis. Osteosarcoma / diagnosis
  • [MeSH-minor] Adult. Cell Differentiation. Femur. Humans. Lung Neoplasms / secondary. Male

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathology. 1999 Nov;31(4):428-30 [10643020.001]
  • [Cites] J Bone Joint Surg Br. 2000 Jan;82(1):55-61 [10697315.001]
  • [Cites] Ann Diagn Pathol. 2002 Jun;6(3):159-63 [12089726.001]
  • [Cites] Cancer. 1971 Aug;28(2):461-6 [5566365.001]
  • [Cites] J Bone Joint Surg Am. 1986 Oct;68(8):1197-205 [3021775.001]
  • [Cites] Am J Surg Pathol. 1996 Mar;20(3):293-8 [8772782.001]
  • [Cites] Cancer. 1976 Dec;38(6):2538-47 [1069603.001]
  • (PMID = 17071806.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1860503
  •  go-up   go-down


3. Dickerson ME, Page RL, LaDue TA, Hauck ML, Thrall DE, Stebbins ME, Price GS: Retrospective analysis of axial skeleton osteosarcoma in 22 large-breed dogs. J Vet Intern Med; 2001 Mar-Apr;15(2):120-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective analysis of axial skeleton osteosarcoma in 22 large-breed dogs.
  • Medical-records of 22 large-breed dogs (>15 kg) with osteosarcoma (OSA) of the axial skeleton were reviewed to determine prevalence of metastasis and survival associated with this neoplasm.
  • All dogs were treated with more than 1 mode of therapy including palliative radiation (n = 12), definitive radiation (n = 8), surgery (n = 7), chemotherapy (n = 12), or some combination of these therapies.
  • Breed (retriever versus purebred versus mixed-breed survival was 100, 182, and 264 days, respectively) and radiation therapy protocol (survival in dogs treated with palliative radiation therapy versus those treated with definitive radiation therapy was 79 and 265 days, respectively) were significantly related to survival (P < .05).
  • Definitive radiation therapy may have a role in the treatment of axial skeleton osteosarcoma.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11300594.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Wittig JC, Bickels J, Priebat D, Jelinek J, Kellar-Graney K, Shmookler B, Malawer MM: Osteosarcoma: a multidisciplinary approach to diagnosis and treatment. Am Fam Physician; 2002 Mar 15;65(6):1123-32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteosarcoma: a multidisciplinary approach to diagnosis and treatment.
  • The treatment of osteosarcoma requires a multidisciplinary approach involving the family physician, orthopedic oncologist, medical oncologist, radiologist and pathologist.
  • Osteosarcoma is a mesenchymally derived, high-grade bone sarcoma.
  • The most frequent sites of origin are the distal femur, proximal tibia and proximal humerus.
  • Radiographs commonly demonstrate a mixed sclerotic and lytic lesion arising in the metaphyseal region of the involved bone.
  • Computed tomography and bone scanning are recommended to detect pulmonary and bone metastases, respectively.
  • With the development of induction and adjuvant chemotherapy protocols, advances in surgical techniques and improvements in radiologic staging studies, 90 to 95 percent of patients with osteosarcoma can now be treated with limb-sparing resection and reconstruction.
  • [MeSH-major] Bone Neoplasms / diagnosis. Bone Neoplasms / therapy. Osteosarcoma / diagnosis. Osteosarcoma / therapy
  • [MeSH-minor] Humans. Magnetic Resonance Imaging. Neoplasm Staging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11925089.001).
  • [ISSN] 0002-838X
  • [Journal-full-title] American family physician
  • [ISO-abbreviation] Am Fam Physician
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 29
  •  go-up   go-down


5. Wei-wei L, Qiu-liang W, Guo-hao W, Zhi-hua C, Zong-yuan Z: Clinicopathologic features, treatment, and prognosis of postirradiation osteosarcoma in patients with nasopharyngeal cancer. Laryngoscope; 2005 Sep;115(9):1574-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic features, treatment, and prognosis of postirradiation osteosarcoma in patients with nasopharyngeal cancer.
  • OBJECTIVES: Postirradiation osteosarcoma (PIOS) arising after radiation of nasopharyngeal cancer (NPC) is rare and seldom reported.
  • METHODS: Fifteen patients with NPC were determined to have PIOS after reviewing 426 patients with osteogenic sarcomas.
  • Their clinical records, image and pathologic slides, and follow-up data after treatment were collected to perform analysis.
  • RESULTS: The incidence rate of PIOS in NPC was approximately 0.037% (15/40,719), which occupied approximately 3.5% (15/426) among all kinds of osteogenic sarcomas.
  • The latent time of PIOS after irradiation for NPC ranged from 4 to 27 years, with a mean of 13.3 years.
  • Radiologically, soft tissue mass, bone destruction, and tumor new bone formation were the main characteristics.
  • Pathologic subtypes included 53.3% (8/15) of fibroblastic osteosarcoma, 33.3% (5/15) of chondroblastic osteosarcoma, and 13.3% (2/15) of mixed type osteosarcoma.
  • The survival time after treatment for all patients ranged from 7 to 41 months, with a mean of 18 months.
  • Surgery combined with pre- and postoperative chemotherapy might be an effective way to improve survival.
  • [MeSH-major] Nasopharyngeal Neoplasms / radiotherapy. Neoplasms, Radiation-Induced / pathology. Neoplasms, Second Primary / pathology. Osteosarcoma / pathology
  • [MeSH-minor] Adolescent. Adult. Cohort Studies. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Mandibular Neoplasms / pathology. Maxillary Neoplasms / pathology. Middle Aged. Nasal Cavity. Nose Neoplasms / pathology. Paranasal Sinus Neoplasms / pathology. Prognosis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Osteosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16148697.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Allam-Nandyala P, Bui MM, Caracciolo JT, Hakam A: Squamous cell carcinoma and osteosarcoma arising from a dermoid cyst--a case report and review of literature. Int J Clin Exp Pathol; 2010;3(3):313-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma and osteosarcoma arising from a dermoid cyst--a case report and review of literature.
  • A rare case of multiple malignant tumors (poorly differentiated squamous cell carcinoma and high grade osteosarcoma) arising in an ovarian dermoid cyst of a 55 year old female is reported.
  • The osteosarcoma and squamous cell carcinoma appear to arise in the background of benign teratomatous environment of a dermoid cyst rather than from "pure" mixed mesodermal tumors of the ovary.
  • The tumors did not appear to have well demarcated boundaries with a junction or close intermingling of both cell types, features less favorable for collision tumor or carcinosarcoma.
  • Despite extensive surgery with negative surgical margins and combination chemotherapy, the patient had recurrence of the tumor within four months and she died secondary to septicemia to chemotherapy and bilateral pulmonary emboli shortly after.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Dermoid Cyst / pathology. Osteosarcoma / secondary. Ovarian Neoplasms / pathology
  • [MeSH-minor] Combined Modality Therapy. Diagnosis, Differential. Fatal Outcome. Female. Humans. Middle Aged. Ovary / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Hematol Oncol. 2003 May;25(5):410-3 [12759630.001]
  • [Cites] Acta Pathol Jpn. 1981 Jul;31(4):681-8 [7282367.001]
  • [Cites] Gynecol Oncol. 1990 Apr;37(1):143-7 [2182405.001]
  • [Cites] Indian J Cancer. 1993 Sep;30(3):140-2 [8300145.001]
  • [Cites] Saudi Med J. 2009 Apr;30(4):524-8 [19370280.001]
  • [Cites] J Exp Clin Cancer Res. 1999 Mar;18(1):89-91 [10374685.001]
  • [Cites] Obstet Gynecol. 1954 Nov;4(5):567-71 [13214667.001]
  • [Cites] Cancer. 1961 Sep-Oct;14:989-1000 [13752348.001]
  • [Cites] BMC Cancer. 2006;6:47 [16509974.001]
  • [Cites] J Clin Pathol. 1996 Jun;49(6):519-21 [8763274.001]
  • (PMID = 20224730.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 14
  • [Other-IDs] NLM/ PMC2836509
  • [Keywords] NOTNLM ; Malignant dermoid / osteosarcoma / squamous cell carcinoma / teratoma
  •  go-up   go-down


7. Yuen L: Primary sarcoma of the ribs in a large, mixed breed dog. Can Vet J; 2000 Jan;41(1):63-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary sarcoma of the ribs in a large, mixed breed dog.
  • A 9-year-old, 30-kg, neutered male, mixed breed dog was referred for en bloc resection of a tentatively diagnosed costal chondrosarcoma.
  • Light microscopic examination of the excised mass confirmed osteosarcoma.
  • Adjuvant chemotherapy with 4 treatments with carboplatin was initiated.
  • [MeSH-major] Bone Neoplasms / veterinary. Dog Diseases / diagnosis. Osteosarcoma / veterinary
  • [MeSH-minor] Animals. Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. Dogs. Male. Ribs / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Vet Intern Med. 1991 Jul-Aug;5(4):205-10 [1941754.001]
  • [Cites] J Vet Intern Med. 1988 Oct-Dec;2(4):177-80 [3230557.001]
  • [Cites] J Am Vet Med Assoc. 1982 Apr 15;180(8):927-33 [6953063.001]
  • [Cites] Clin Orthop Relat Res. 1969 Jan-Feb;62:54-64 [5251443.001]
  • [Cites] J Vet Intern Med. 1996 Mar-Apr;10(2):76-81 [8683484.001]
  • [Cites] J Am Anim Hosp Assoc. 1995 Jan-Feb;31(1):65-9 [7820767.001]
  • [Cites] Vet Surg. 1992 May-Jun;21(3):201-4 [1626394.001]
  • [Cites] Vet Surg. 1992 Jul-Aug;21(4):304-10 [1455640.001]
  • (PMID = 10642875.001).
  • [ISSN] 0008-5286
  • [Journal-full-title] The Canadian veterinary journal = La revue vétérinaire canadienne
  • [ISO-abbreviation] Can. Vet. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] CANADA
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin
  • [Other-IDs] NLM/ PMC1476333
  •  go-up   go-down


8. Kim HS, Park YB, Oh JH, Yoo KH, Lee SH: The cytotoxic effect of methotrexate loaded bone cement on osteosarcoma cell lines. Int Orthop; 2001;25(6):343-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The cytotoxic effect of methotrexate loaded bone cement on osteosarcoma cell lines.
  • We mixed various amounts of methotrexate with bone cement and measured the absorbance daily for 4 weeks.
  • The cytotoxic effects on SaOS2 and MG63 osteosarcoma cells were examined by the MTT assay, and analysed according to the methotrexate concentration and the elapsed time.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Bone Cements. Bone Neoplasms / drug therapy. Drug Delivery Systems. Methotrexate / administration & dosage
  • [MeSH-minor] Drug Screening Assays, Antitumor. Humans. Osteosarcoma / drug therapy. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11820438.001).
  • [ISSN] 0341-2695
  • [Journal-full-title] International orthopaedics
  • [ISO-abbreviation] Int Orthop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Bone Cements; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ PMC3620791
  •  go-up   go-down


9. Wengerkievicz AC, Corá AP, de Almeida LP, Duarte NJ, Siqueira SA, Antonangelo L: Neoplastic ascites in osteosarcoma: a case report. Acta Cytol; 2010 Sep-Oct;54(5 Suppl):845-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoplastic ascites in osteosarcoma: a case report.
  • BACKGROUND: Osteosarcoma is a malignant tumor of connective tissue whose tumor cells produce bone tissue.
  • It can be classified as osteoblastic, chondroblastic, or fibroblastic, according to the predominant histologic type of cells.
  • We present a case of osteosarcoma with peritoneal dissemination that developed neoplastic ascites.
  • Computed tomography showed blastic lesions in the L3 vertebral body.
  • Surgical resection and histologic analysis revealed a mixed osteoblastic and chondroblastic osteosarcoma.
  • After only one session of chemotherapy, the patient presented a marked clinical worsening with extensive metastatic dissemination and occurrence of voluminous ascites.
  • CONCLUSION: This case is the only report of osteosarcoma primarily focused on the vertebral column affected by peritoneal metastasis shown by cytologic examination of ascitic fluid.
  • [MeSH-major] Ascites / pathology. Osteosarcoma / pathology. Spinal Neoplasms / pathology

  • Genetic Alliance. consumer health - Osteosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21053553.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Aygun B, Kimpo M, Lee T, Valderrama E, Leonidas J, Karayalcin G: An adolescent with ovarian osteosarcoma arising in a cystic teratoma. J Pediatr Hematol Oncol; 2003 May;25(5):410-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An adolescent with ovarian osteosarcoma arising in a cystic teratoma.
  • A 14-year-old girl had an abdominal mass with the characteristics of an ovarian germ cell tumor on computed tomography scan.
  • The mass, arising from the left ovary, was completely resected and found to be osteosarcoma arising from a mature cystic teratoma.
  • Seven months after completion of chemotherapy, there were simultaneous local recurrence and lung metastases.
  • Previously, 10 cases of ovarian osteosarcoma have been reported in the literature: 5 were primary osteosarcoma of the ovary, 4 were associated with teratomas, and 1 was part of a malignant mixed mesodermal tumor of the ovary.
  • Of the 10, there are only 2 long-term survivors, both of whom were treated with adjuvant chemotherapy following complete resection.
  • [MeSH-major] Osteosarcoma / pathology. Ovarian Neoplasms / pathology. Teratoma / pathology

  • Genetic Alliance. consumer health - Osteosarcoma.
  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12759630.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down


11. Anderson PM, Wiseman GA, Erlandson L, Rodriguez V, Trotz B, Dubansky SA, Albritton K: Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma. Clin Cancer Res; 2005 Oct 1;11(19 Pt 1):6895-900
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma.
  • Osteoblastic metastases and osteosarcoma can avidly concentrate bone-seeking radiopharmaceuticals.
  • All patients received autologous stem cell reinfusion 2 weeks after 153Sm to correct expected grade 4 hematopoietic toxicity.
  • At the 6- to 8-week follow-up, there were six partial remissions, two mixed responses, and six patients with progressive disease.
  • Thus, although high-dose 153Sm-EDTMP + gemcitabine has moderate palliative activity (improved pain; radiologic responses) in this poor-risk population, additional measures of local and systemic control are required for durable control of relapsed osteosarcoma with osteoblastic lesions.
  • The strategy of radioactive drug binding to a target followed by a radiosensitizer may provide synergy and improved response rate.
  • [MeSH-major] Bone Neoplasms / pathology. Combined Modality Therapy / methods. Deoxycytidine / analogs & derivatives. Osteosarcoma / pathology. Osteosarcoma / therapy. Radiation-Sensitizing Agents / pharmacology
  • [MeSH-minor] Adolescent. Adult. Alkaline Phosphatase / metabolism. Analgesics, Non-Narcotic / pharmacology. Antigens, CD34 / biosynthesis. Bone and Bones / metabolism. Humans. Image Processing, Computer-Assisted. Neoplasm Metastasis. Organometallic Compounds / pharmacology. Organophosphorus Compounds / pharmacology. Pain / drug therapy. Positron-Emission Tomography. Radiopharmaceuticals / pharmacology. Remission Induction. Samarium / chemistry. Sarcoma / metabolism. Stem Cells / cytology. Time Factors

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Samarium, Elemental .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16203780.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics, Non-Narcotic; 0 / Antigens, CD34; 0 / Organometallic Compounds; 0 / Organophosphorus Compounds; 0 / Radiation-Sensitizing Agents; 0 / Radiopharmaceuticals; 0W860991D6 / Deoxycytidine; 122575-21-7 / samarium ethylenediaminetetramethylenephosphonate; 42OD65L39F / Samarium; B76N6SBZ8R / gemcitabine; EC 3.1.3.1 / Alkaline Phosphatase
  •  go-up   go-down


12. Weinstein JI, Payne S, Poulson JM, Azuma C: Use of force plate analysis to evaluate the efficacy of external beam radiation to alleviate osteosarcoma pain. Vet Radiol Ultrasound; 2009 Nov-Dec;50(6):673-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of force plate analysis to evaluate the efficacy of external beam radiation to alleviate osteosarcoma pain.
  • A standard of therapy for osteosarcoma includes amputation with or without adjuvant chemotherapy.
  • There is a subset of dogs with osteosarcoma that are unsuitable for amputation.
  • We evaluated kinetic variables in dogs with appendicular osteosarcoma treated with a single 8 Gy dose of radiation.
  • Eighteen pet dogs with appendicular osteosarcoma received one 8 Gy fraction of palliative radiation on day 0.
  • There were no significant changes in kinetic parameters after one 8 Gy dose of radiation therapy.
  • There was a significant correlation between Fz and response to therapy based on SI at day 21.
  • SI seems to be useful to objectively assess response in this mixed population of dogs.
  • One 8 Gy fraction of radiation therapy alone did not reduce lameness associated with appendicular osteosarcoma, but a subset of dogs did have improved limb function after a single dose.
  • [MeSH-major] Dog Diseases / radiotherapy. Exercise Test / veterinary. Osteosarcoma / veterinary. Pain Management
  • [MeSH-minor] Animals. Dogs. Female. Gait. Lameness, Animal / etiology. Lameness, Animal / radiotherapy. Male. Pain / etiology. Pain / veterinary. Palliative Care / methods. Particle Accelerators. Radiation Dosage. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19999356.001).
  • [ISSN] 1058-8183
  • [Journal-full-title] Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association
  • [ISO-abbreviation] Vet Radiol Ultrasound
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


13. McTiernan A, Whelan JS: A Phase II Study of Docetaxel for the Treatment of Recurrent Osteosarcoma. Sarcoma; 2004;8(2-3):71-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Phase II Study of Docetaxel for the Treatment of Recurrent Osteosarcoma.
  • PURPOSE: To determine the response and toxicity of docetaxel in recurrent osteosarcoma and related spindle cell tumours of bone.
  • Diagnosis was: conventional osteosarcoma, 12 patients; periosteal osteosarcoma, one patient; and malignant fibrous histiocytoma of bone, one patient.
  • Initial chemotherapy had been with doxorubicin and cisplatin in 10 patients, and multiagent regimens in four.
  • Nine had been treated with second line chemotherapy before receiving docetaxel.
  • Two patients had stable disease, and one patient a mixed response.
  • CONCLUSION: Docetaxel at this dose and schedule is well tolerated, but is not associated with significant activity in patients with relapsed osteosarcoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3016-24 [12837811.001]
  • [Cites] Ann Oncol. 1998 Aug;9(8):893-9 [9789613.001]
  • [Cites] J Natl Cancer Inst. 1991 Feb 20;83(4):288-91 [1671606.001]
  • [Cites] J Natl Cancer Inst. 1991 Dec 18;83(24):1797-805 [1683908.001]
  • [Cites] Sarcoma. 2003;7(1):13-7 [18521364.001]
  • [Cites] Clin Cancer Res. 1999 Apr;5(4):733-7 [10213206.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2341-54 [10561296.001]
  • [Cites] Ann Intern Med. 1989 Aug 15;111(4):273-9 [2569287.001]
  • [Cites] Br J Cancer. 1995 Oct;72(4):1016-9 [7547214.001]
  • [Cites] Cancer. 1995 Mar 1;75(5):1084-93 [7850705.001]
  • [Cites] Am J Clin Oncol. 2000 Apr;23(2):132-9 [10776972.001]
  • [Cites] J Clin Oncol. 2000 May;18(10):2081-6 [10811673.001]
  • [Cites] Clin Orthop Relat Res. 2001 Feb;(383):259-67 [11210963.001]
  • [Cites] Br J Cancer. 2001 Mar 2;84(5):604-10 [11237379.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2001 May;23(3):190-2 [11783082.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):776-90 [11821461.001]
  • [Cites] J Clin Oncol. 2003 Feb 15;21(4):710-5 [12586810.001]
  • [Cites] Eur J Cancer. 2003 Mar;39(4):488-94 [12751380.001]
  • [Cites] Br J Cancer. 1994 Aug;70(2):380-3 [7914428.001]
  • [Cites] Ann Oncol. 1994 Jul;5(6):539-42 [7918126.001]
  • [Cites] J Natl Cancer Inst. 1993 Mar 3;85(5):384-8 [8094466.001]
  • [Cites] Cancer. 1996 Aug 15;78(4):741-4 [8756366.001]
  • [Cites] Am J Clin Oncol. 1996 Dec;19(6):574-6 [8931674.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):750-8 [9053501.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):1071-9 [9060547.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1538-43 [9193350.001]
  • [Cites] Lancet. 1997 Sep 27;350(9082):911-7 [9314869.001]
  • [Cites] J Chemother. 1998 Feb;10(1):69-76 [9531078.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2452-8 [9667263.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Jul;25(7):539-42 [12847320.001]
  • (PMID = 18521398.001).
  • [ISSN] 1357-714X
  • [Journal-full-title] Sarcoma
  • [ISO-abbreviation] Sarcoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2395610
  •  go-up   go-down


14. Labrinidis A, Hay S, Liapis V, Findlay DM, Evdokiou A: Zoledronic acid protects against osteosarcoma-induced bone destruction but lacks efficacy against pulmonary metastases in a syngeneic rat model. Int J Cancer; 2010 Jul 15;127(2):345-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Zoledronic acid protects against osteosarcoma-induced bone destruction but lacks efficacy against pulmonary metastases in a syngeneic rat model.
  • Osteosarcoma (OS) is the most common primary malignant tumor of bone in children and adolescents.
  • OS development was associated with osteolysis mixed with new bone formation, adjacent to the periosteum and extended into the surrounding soft tissue.
  • Metastatic foci in the lungs formed 3-4 weeks postcancer cell transplantation.
  • Treatment with a clinically relevant dose of ZOL was initiated 1 week after tumors were established and continued once weekly or as a single dose.
  • However, the overall tumor burden at the primary site was not reduced because of the persistent growth of cancer cells in the extramedullary space, which was not affected by ZOL treatment.
  • ZOL treatment failed to prevent the metastatic spread of OS to the lungs.
  • ZOL may have potential value as an adjuvant therapy in patients with established OS.
  • [MeSH-major] Bone Density Conservation Agents / pharmacology. Bone Neoplasms / prevention & control. Bone Resorption / prevention & control. Diphosphonates / pharmacology. Imidazoles / pharmacology. Lung Neoplasms / pathology. Osteosarcoma / prevention & control
  • [MeSH-minor] Animals. Apoptosis / drug effects. Blotting, Western. Caspases / metabolism. Cell Proliferation / drug effects. Male. Rats. Rats, Inbred F344

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19924813.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; 0 / Diphosphonates; 0 / Imidazoles; 6XC1PAD3KF / zoledronic acid; EC 3.4.22.- / Caspases
  •  go-up   go-down


15. Labrinidis A, Hay S, Liapis V, Ponomarev V, Findlay DM, Evdokiou A: Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model. Clin Cancer Res; 2009 May 15;15(10):3451-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model.
  • PURPOSE: To evaluate the efficacy of zoledronic acid (ZOL) against osteosarcoma (OS) growth, progression, and metastatic spread using an animal model of human OS that closely resembles the human disease.
  • Tumor growth at the primary site and as pulmonary metastases was monitored by bioluminescence imaging and histology, and OS-induced bone destruction was measured using high-resolution micro-computed tomography.
  • RESULTS: Mice transplanted with OS cells exhibited aberrant bone remodeling in the area of cancer cell transplantation, with areas of osteolysis mixed with extensive new bone formation extending from the cortex.
  • Moreover, lung metastases were not reduced and may even have been promoted by this treatment, indicating that caution is required when the clinical application of the bisphosphonate class of antiresorptives is considered in OS.
  • [MeSH-major] Diphosphonates / pharmacology. Imidazoles / pharmacology. Osteoblasts / drug effects. Osteolysis / prevention & control. Osteosarcoma / drug therapy
  • [MeSH-minor] Animals. Apoptosis / drug effects. Bone Density Conservation Agents / pharmacology. Cell Line, Tumor. Cell Proliferation / drug effects. Disease Progression. Dose-Response Relationship, Drug. Female. Green Fluorescent Proteins / genetics. Green Fluorescent Proteins / metabolism. Humans. Luciferases / genetics. Luciferases / metabolism. Luminescent Measurements / methods. Mice. Mice, Inbred BALB C. Mice, Nude. Recombinant Fusion Proteins / genetics. Recombinant Fusion Proteins / metabolism. Tibia / drug effects. Tibia / pathology. Tumor Burden / drug effects. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Osteosarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast. 2003 Aug;12 Suppl 2:S37-44 [14659142.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):584-93 [12154351.001]
  • [Cites] Int J Cancer. 2008 Feb 15;122(4):751-60 [17960623.001]
  • [Cites] J Clin Oncol. 2001 Jul 15;19(14):3434-7 [11454892.001]
  • [Cites] Cancer. 1997 Oct 15;80(8 Suppl):1581-7 [9362425.001]
  • [Cites] Crit Rev Eukaryot Gene Expr. 2000;10(2):159-78 [11186331.001]
  • [Cites] Annu Rev Biochem. 1996;65:241-69 [8811180.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6015-20 [12414621.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2602-8 [11289137.001]
  • [Cites] Clin Orthop Relat Res. 1991 Sep;(270):8-14 [1884563.001]
  • [Cites] Br J Cancer. 2002 Jul 29;87(3):366-71 [12177810.001]
  • [Cites] Acta Orthop Scand Suppl. 1997 Feb;273:120-5 [9057601.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):295-306 [12538482.001]
  • [Cites] Bone. 1985;6(6):433-7 [2937428.001]
  • [Cites] Cancer. 2000 Jun 15;88(12 Suppl):3054-8 [10898351.001]
  • [Cites] J Bone Miner Res. 2001 Nov;16(11):2027-34 [11697798.001]
  • [Cites] Calcif Tissue Res. 1975 Sep 5;18(3):215-31 [810231.001]
  • [Cites] Int J Hematol. 2004 Jan;79(1):37-43 [14979476.001]
  • [Cites] Pediatr Blood Cancer. 2004 May;42(5):410-5 [15049011.001]
  • [Cites] J Clin Invest. 2001 May;107(10):1219-20 [11375409.001]
  • [Cites] J Natl Cancer Inst. 2007 Feb 21;99(4):322-30 [17312309.001]
  • [Cites] Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3263-70 [18089720.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5564-70 [12359769.001]
  • [Cites] Breast Cancer Res. 2002;4(1):18-23 [11879555.001]
  • [Cites] Cancer. 2005 Dec 1;104(11):2522-9 [16270320.001]
  • [Cites] Calcif Tissue Res. 1973 Mar 12;11(3):196-214 [4707191.001]
  • [Cites] Cancer Res. 1993 Oct 15;53(20):4890-5 [8402677.001]
  • [Cites] Bone. 1994 Mar-Apr;15(2):161-6 [8086233.001]
  • [Cites] Oncologist. 2004;9 Suppl 4:3-13 [15459425.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 2004 Mar-Apr;40(3-4):113-7 [15311969.001]
  • [Cites] Bibl Haematol. 1975 Oct;(43):84-7 [183736.001]
  • [Cites] J Immunol. 1996 Jan 15;156(2):611-20 [8543812.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 May;31(5):740-51 [15014901.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5363-70 [16707463.001]
  • [Cites] Anticancer Drugs. 2003 Oct;14(9):767-71 [14551512.001]
  • [Cites] Calcif Tissue Int. 1983;35(1):87-99 [6839194.001]
  • [Cites] Bone. 2005 Jul;37(1):74-86 [15894525.001]
  • [Cites] Bone. 2003 Aug;33(2):216-28 [14499355.001]
  • [Cites] Clin Cancer Res. 2009 Mar 15;15(6):1998-2009 [19276263.001]
  • [Cites] J Natl Cancer Inst. 1997 Nov 19;89(22):1706-15 [9390540.001]
  • [Cites] Anticancer Drugs. 2001 Jun;12(5):459-65 [11395574.001]
  • [Cites] Cancer. 2000 Jun 15;88(12 Suppl):2903-8 [10898332.001]
  • [Cites] Br J Cancer. 2003 Jun 16;88(12 ):1971-8 [12799645.001]
  • (PMID = 19401351.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA008748
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; 0 / Diphosphonates; 0 / Imidazoles; 0 / Recombinant Fusion Proteins; 147336-22-9 / Green Fluorescent Proteins; 6XC1PAD3KF / zoledronic acid; EC 1.13.12.- / Luciferases
  •  go-up   go-down


16. Seiple LA, Cardellina JH 2nd, Akee R, Stivers JT: Potent inhibition of human apurinic/apyrimidinic endonuclease 1 by arylstibonic acids. Mol Pharmacol; 2008 Mar;73(3):669-77
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human apurinic/apyrimidinic endonuclease (Ape1) plays an important role by processing the >10,000 highly toxic abasic sites generated in the genome of each cell every day.
  • Ape1 has recently emerged as a target for inhibition, in that its overexpression in tumors has been linked with poor response to both radiation and chemotherapy and lower overall patient survival.
  • The negatively charged stibonic acids act by a partial-mixed mode and probably serve as DNA phosphate mimics.

  • COS Scholar Universe. author profiles.
  • BindingDB. BindingDB .
  • Hazardous Substances Data Bank. ANTIMONY, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Jan 27;403(6768):451-6 [10667800.001]
  • [Cites] EMBO J. 1992 Feb;11(2):653-65 [1537340.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):824-30 [11309329.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 May 1;50(1):27-36 [11316543.001]
  • [Cites] J Am Chem Soc. 2001 Jun 27;123(25):5878-91 [11414820.001]
  • [Cites] Mutat Res. 2001 May 10;485(4):283-307 [11585362.001]
  • [Cites] Oncol Rep. 2002 Jan-Feb;9(1):11-7 [11748448.001]
  • [Cites] Anticancer Res. 2001 Nov-Dec;21(6A):4041-9 [11911289.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):3008-18 [12231548.001]
  • [Cites] Mol Cancer Ther. 2003 Oct;2(10):1061-6 [14578471.001]
  • [Cites] Mutat Res. 2003 Oct 29;531(1-2):157-63 [14637252.001]
  • [Cites] DNA Repair (Amst). 2004 Jan 5;3(1):1-12 [14697754.001]
  • [Cites] Gynecol Oncol. 2004 Feb;92(2):568-77 [14766249.001]
  • [Cites] EMBO J. 1992 Sep;11(9):3323-35 [1380454.001]
  • [Cites] Nucleic Acids Res. 1994 Nov 25;22(23):4884-9 [7800476.001]
  • [Cites] J Biol Chem. 1995 Jul 7;270(27):16002-7 [7608159.001]
  • [Cites] Anal Biochem. 1996 Jun 1;237(2):260-73 [8660575.001]
  • [Cites] Genes Dev. 1997 Mar 1;11(5):558-70 [9119221.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1133-7 [9169823.001]
  • [Cites] Anticancer Res. 1997 Sep-Oct;17(5B):3713-19 [9427767.001]
  • [Cites] Nucleic Acids Res. 1998 Jun 1;26(11):2771-8 [9592167.001]
  • [Cites] Br J Cancer. 1998 Nov;78(9):1128-33 [9820167.001]
  • [Cites] J Virol. 2005 May;79(10):6122-33 [15857997.001]
  • [Cites] Cancer Lett. 2005 Jun 16;224(1):133-9 [15911109.001]
  • [Cites] Nucleic Acids Res. 2005;33(15):4711-24 [16113242.001]
  • [Cites] J Am Chem Soc. 2005 Dec 14;127(49):17412-20 [16332091.001]
  • [Cites] Mol Cancer Ther. 2005 Dec;4(12):1923-35 [16373707.001]
  • [Cites] Biochem Pharmacol. 2006 Jan 12;71(3):257-67 [16318845.001]
  • [Cites] Mol Pharmacol. 2006 Feb;69(2):547-57 [16267207.001]
  • [Cites] Bioorg Med Chem. 2006 Aug 15;14(16):5666-72 [16678429.001]
  • [Cites] Nucleic Acids Res. 2006;34(20):5872-9 [17062624.001]
  • [Cites] Mol Cancer Res. 2007 Jan;5(1):61-70 [17259346.001]
  • [Cites] Curr Med Chem. 2007;14(10):1153-69 [17456028.001]
  • [Cites] Mol Aspects Med. 2007 Jun-Aug;28(3-4):375-95 [17560642.001]
  • [Cites] Mol Cancer Ther. 2004 Jun;3(6):679-86 [15210853.001]
  • [Cites] Anticancer Res. 2004 Jul-Aug;24(4):2127-34 [15330152.001]
  • [Cites] Biochemistry. 1972 Sep 12;11(19):3610-8 [4626532.001]
  • [Cites] J Biol Chem. 1985 May 10;260(9):5252-8 [2580833.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2220-5 [11280790.001]
  • (PMID = 18042731.001).
  • [ISSN] 1521-0111
  • [Journal-full-title] Molecular pharmacology
  • [ISO-abbreviation] Mol. Pharmacol.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM056834-12; United States / NIGMS NIH HHS / GM / GM056834-12; United States / NIGMS NIH HHS / GM / GM56834; United States / NCI NIH HHS / CA / N01CO12400; United States / NIGMS NIH HHS / GM / R01 GM056834; United States / NCI NIH HHS / CO / N01-CO-12400
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Ligands; 0 / Recombinant Proteins; 9007-49-2 / DNA; 9IT35J3UV3 / Antimony; EC 3.1.- / Endonucleases; EC 4.2.99.18 / DNA-(Apurinic or Apyrimidinic Site) Lyase
  • [Other-IDs] NLM/ NIHMS121522; NLM/ PMC2720577
  •  go-up   go-down


17. Gastmeier K, Freye E: [High-dose buprenorphine for outpatient palliative pain therapy]. Schmerz; 2009 Apr;23(2):180-6
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [High-dose buprenorphine for outpatient palliative pain therapy].
  • The case of a 78-year-old patient with cancer-related pain and additionally mixed-pain syndrome is presented.
  • Pain therapy with buprenorphine TTS 210 microg/h every 3 days was sufficient in the beginning, later the therapy was changed because of increasing problems of tape fixing during fever periods under chemotherapy to a continuous infusion of buprenorphine intravenously via an external medication pump.
  • During the course of therapy it became necessary to increase the dose to 99.9 mg/day buprenorphine.
  • Under this medication a sufficient pain reduction (median NRS 2-3) over a period of 135 days could be achieved.
  • At the same time the patient was vigilant and cooperative without signs of intoxication until the end of life at home in the presence of his family.If no signs of intoxication occur under extreme opioid therapy and a sufficient pain therapy can be achieved, a rotation to another opioid is not necessary.
  • However, outpatient palliative care requires a frequent adaptation to the individually varying opioid demand of the patient and time-consuming nursing care.
  • [MeSH-major] Analgesics, Opioid / administration & dosage. Buprenorphine / administration & dosage. Femoral Neoplasms / physiopathology. Osteosarcoma / physiopathology. Pain, Intractable / drug therapy. Palliative Care
  • [MeSH-minor] Aged. Combined Modality Therapy. Comorbidity. Disease Progression. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Therapy, Combination. Humans. Infusion Pumps, Implantable. Length of Stay. Male. Neoplasm Staging. Pain Measurement / drug effects. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuropsychopharmacology. 2003 Nov;28(11):2000-9 [12902992.001]
  • [Cites] Clin Rheumatol. 2002 Feb;21 Suppl 1:S13-6 [11954897.001]
  • [Cites] Br J Pharmacol. 1981 Nov;74(3):627-33 [6271322.001]
  • [Cites] J Pharmacol Exp Ther. 1998 Jan;284(1):283-90 [9435189.001]
  • [Cites] Pain. 2005 Nov;118(1-2):15-22 [16154698.001]
  • [Cites] J Pain Symptom Manage. 2003 Jan;25(1):74-91 [12565191.001]
  • [Cites] Biopolymers. 2005;80(2-3):319-24 [15795927.001]
  • [Cites] Anesth Analg. 2008 Feb;106(2):645-6, table of contents [18227327.001]
  • [Cites] Schmerz. 1999 Aug 19;13(4):253-8 [12799925.001]
  • [Cites] J Neurosci. 2002 Aug 1;22(15):6747-55 [12151554.001]
  • [Cites] Anesth Analg. 1996 Sep;83(3):600-5 [8780289.001]
  • [Cites] J Pain Symptom Manage. 2008 Mar;35(3):327-33 [18222628.001]
  • [Cites] Pain. 2003 Nov;106(1-2):49-57 [14581110.001]
  • [Cites] Clin Ther. 2005 Feb;27(2):225-37 [15811486.001]
  • [Cites] Pain. 1995 Jul;62(1):51-60 [7478708.001]
  • [Cites] Clin Ther. 2004 Nov;26(11):1808-20 [15639693.001]
  • [Cites] Arch Gen Psychiatry. 2007 Mar;64(3):369-76 [17339526.001]
  • [Cites] Pain. 1997 Jan;69(1-2):199-201 [9060031.001]
  • [Cites] Br J Pharmacol. 1977 Aug;60(4):537-45 [409448.001]
  • [Cites] J Clin Oncol. 2007 Oct 1;25(28):4497-8 [17906213.001]
  • [Cites] Mol Pharmacol. 1999 Aug;56(2):396-403 [10419560.001]
  • [Cites] Anesthesiology. 2002 Feb;96(2):381-91 [11818772.001]
  • [Cites] Pain Pract. 2007 Jun;7(2):123-9 [17559481.001]
  • [Cites] Am J Hosp Palliat Care. 2005 Jul-Aug;22(4):291-4 [16082916.001]
  • [Cites] J Nerv Ment Dis. 1993 Jun;181(6):358-64 [8501457.001]
  • [Cites] J Pharmacol Exp Ther. 1998 Jun;285(3):1157-62 [9618418.001]
  • [Cites] Clin J Pain. 2007 Sep;23(7):605-11 [17710011.001]
  • [Cites] Anesthesiology. 2006 Aug;105(2):334-7 [16871067.001]
  • [Cites] Clin Pharmacol Ther. 1994 May;55(5):569-80 [8181201.001]
  • [Cites] Support Care Cancer. 2007 Apr;15(4):441-4 [17106658.001]
  • [Cites] Pain. 1995 Sep;62(3):259-74 [8657426.001]
  • [Cites] Anesthesiology. 2000 Feb;92(2):465-72 [10691234.001]
  • [Cites] Acta Anaesthesiol Scand. 1998 Oct;42(9):1070-5 [9809090.001]
  • [Cites] Trends Pharmacol Sci. 1994 Mar;15(3):65-6 [8184487.001]
  • [Cites] J Pharmacol Exp Ther. 1988 Feb;244(2):501-7 [3346833.001]
  • [Cites] Anesth Analg. 1998 Nov;87(5):1117-20 [9806692.001]
  • [Cites] Clin Cancer Res. 1998 Apr;4(4):1013-9 [9563897.001]
  • [Cites] Mol Pharmacol. 1993 Jul;44(1):173-9 [8393519.001]
  • [Cites] J Neurosci. 2005 Jan 12;25(2):409-16 [15647484.001]
  • [Cites] Psychopharmacol Bull. 1992;28(1):109-13 [1609035.001]
  • [Cites] Nature. 1997 Apr 17;386(6626):721-4 [9109489.001]
  • [Cites] Anesthesiology. 2006 Mar;104(3):570-87 [16508405.001]
  • [Cites] J Neurosci. 2001 Jun 1;21(11):4074-80 [11356895.001]
  • (PMID = 19066981.001).
  • [ISSN] 1432-2129
  • [Journal-full-title] Schmerz (Berlin, Germany)
  • [ISO-abbreviation] Schmerz
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 40D3SCR4GZ / Buprenorphine
  •  go-up   go-down


18. Würthwein G, Koling S, Reich A, Hempel G, Schulze-Westhoff P, Pinheiro PV, Boos J: Pharmacokinetics of intravenous paracetamol in children and adolescents under major surgery. Eur J Clin Pharmacol; 2005 Feb;60(12):883-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: About 4 weeks after the last chemotherapy, seven children and adolescents (five osteosarcoma, two Ewing tumors) received paracetamol infusion (median: 15.0 mg/kg) for analgesia.
  • Nonlinear mixed-effect models were used to describe the pharmacokinetics of paracetamol in plasma.
  • CONCLUSIONS: Surgery, with all its potential influencing factors, together with chemotherapy given about 4 weeks previously do not seem to have a major impact on the pharmacokinetic behavior and the between-subject variability of paracetamol after intravenous administration.
  • [MeSH-minor] Adolescent. Bone Neoplasms / surgery. Child. Female. Humans. Infusions, Intravenous. Male. Models, Biological. Osteosarcoma / surgery. Perioperative Care. Sarcoma, Ewing / surgery. Surgical Procedures, Operative

  • MedlinePlus Health Information. consumer health - Pain Relievers.
  • Hazardous Substances Data Bank. ACETAMINOPHEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Clin Pharmacol. 1992 Jul;34(1):79-81 [1633071.001]
  • [Cites] Clin Pharmacol Ther. 2000 Mar;67(3):275-82 [10741631.001]
  • [Cites] Eur J Clin Pharmacol. 2003 Jul;59(3):243-51 [12761605.001]
  • [Cites] Eur J Clin Pharmacol. 2001 Oct;57(8):559-69 [11758634.001]
  • [Cites] Clin Pharmacokinet. 1996 May;30(5):329-32 [8743333.001]
  • [Cites] J Chromatogr B Biomed Sci Appl. 1999 Jan 8;721(1):93-108 [10027641.001]
  • [Cites] Dev Pharmacol Ther. 1993;20(3-4):129-34 [7828444.001]
  • [Cites] Clin Pharmacokinet. 1997 Nov;33(5):313-27 [9391745.001]
  • [Cites] Gastroenterology. 1992 Feb;102(2):577-86 [1732127.001]
  • [Cites] Eur J Clin Pharmacol. 1977 Apr 20;11(4):283-6 [862649.001]
  • [Cites] Comput Methods Programs Biomed. 1999 Jan;58(1):51-64 [10195646.001]
  • [Cites] Drugs. 2003;63 Spec No 2:51-6 [14758791.001]
  • [Cites] Science. 1997 Apr 4;276(5309):122-6 [9082983.001]
  • [Cites] Int J Clin Pharmacol Ther. 2004 Jan;42(1):50-7 [14756388.001]
  • [Cites] Arch Dis Child Fetal Neonatal Ed. 2004 Jan;89(1):F25-8 [14711849.001]
  • [Cites] Eur J Clin Pharmacol. 2004 May;60(3):191-7 [15071761.001]
  • [Cites] Eur J Drug Metab Pharmacokinet. 1991 Oct-Dec;16(4):249-55 [1823867.001]
  • [Cites] Br J Clin Pharmacol. 1993 Jan;35(1):58-61 [8448070.001]
  • [Cites] Acta Anaesthesiol Scand. 2003 Feb;47(2):138-45 [12631041.001]
  • (PMID = 15662506.001).
  • [ISSN] 0031-6970
  • [Journal-full-title] European journal of clinical pharmacology
  • [ISO-abbreviation] Eur. J. Clin. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Analgesics, Non-Narcotic; 362O9ITL9D / Acetaminophen
  •  go-up   go-down


19. Arstad E, Hoff P, Skattebøl L, Skretting A, Breistøl K: Studies on the synthesis and biological properties of non-carrier-added [(125)I and (131)I]-labeled arylalkylidenebisphosphonates: potent bone-seekers for diagnosis and therapy of malignant osseous lesions. J Med Chem; 2003 Jul 3;46(14):3021-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Studies on the synthesis and biological properties of non-carrier-added [(125)I and (131)I]-labeled arylalkylidenebisphosphonates: potent bone-seekers for diagnosis and therapy of malignant osseous lesions.
  • The uptake in femur 24h after injection was 850 +/- 265% and 986 +/- 118% of injected dose per gram tissue times gram body weight in mice and rats, respectively.
  • The therapeutic potential of the compound was investigated in two tumor models in athymic (nude) rats, one model for mixed lytic/sclerotic metastatic bone-lesions originating from breast cancer and the other model simulating osseous osteosarcoma.
  • The effects in these models compare favorably to those observed for established treatment modalities.
  • The experiments demonstrate that radioiodinated bisphosphonates may have a potential for diagnosis and therapy of malignant osseous lesions.
  • [MeSH-minor] Animals. Bone Neoplasms / diagnosis. Bone Neoplasms / drug therapy. Bone Neoplasms / mortality. Drug Screening Assays, Antitumor. Humans. Iodine Radioisotopes. Mice. Mice, Inbred BALB C. Neoplasm Transplantation. Osteosarcoma / drug therapy. Osteosarcoma / mortality. Rats. Rats, Nude. Structure-Activity Relationship. Tissue Distribution. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12825941.001).
  • [ISSN] 0022-2623
  • [Journal-full-title] Journal of medicinal chemistry
  • [ISO-abbreviation] J. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Diphosphonates; 0 / Iodine Radioisotopes; 0 / Radiopharmaceuticals
  •  go-up   go-down


20. Zhang H, Xue ZL, Qi AM, Li S, Ye JD: [Antitumor effect of calcium phosphate cement incorporating doxorubicin microspheres]. Nan Fang Yi Ke Da Xue Xue Bao; 2010 Feb;30(2):278-83
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The absorbance at 490 nm of SaoS-2 cells cultured for 5 days in the media containing the extract of the cement incorporating doxorubicin microspheres was measured using Cell Counting Kit-8.
  • The cell suspension (0.1 ml) mixed with an equal volume of the cement extract were injected into the right buttock and on the back of the bilateral ears of nude mice.
  • At 12 days after the cell injection, the tumor tissues were obtained and weighed to calculate the tumor inhibition rate, and the pathological samples were observed with HE staining.
  • CONCLUSIONS: CPC containing doxorubicin PLGA microspheres can inhibit tumor cell growth both in vitro and in vivo.
  • [MeSH-major] Antibiotics, Antineoplastic / pharmacology. Bone Cements / pharmacology. Calcium Phosphates / pharmacology. Doxorubicin / pharmacology. Osteosarcoma / pathology
  • [MeSH-minor] Animals. Bone Neoplasms / drug therapy. Bone Neoplasms / pathology. Cell Line, Tumor. Delayed-Action Preparations. Female. Male. Mice. Mice, Nude. Microspheres

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20159700.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Bone Cements; 0 / Calcium Phosphates; 0 / Delayed-Action Preparations; 80168379AG / Doxorubicin; 97Z1WI3NDX / calcium phosphate
  •  go-up   go-down


21. Jakacki RI, Hamilton M, Gilbertson RJ, Blaney SM, Tersak J, Krailo MD, Ingle AM, Voss SD, Dancey JE, Adamson PC: Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study. J Clin Oncol; 2008 Oct 20;26(30):4921-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At 110 mg/m(2)/d, two of four patients had dose-limiting toxicity (DLT) consisting of rash and hyperbilirubinemia, whereas one of six patients developed dose-limiting rash at 85 mg/m(2)/d.
  • One patient with a neurocytoma had stable disease for 19 months, two patients with neuroblastoma remained on study for 23 and 24 months, and one patient with myoepithelioma had a mixed response.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Cancer. 2007 Oct 1;110(7):1542-50 [17705175.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):2053-63 [10815932.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):6841-5 [11156376.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3267-79 [11432895.001]
  • [Cites] Anticancer Drugs. 2004 Jun;15(5):503-12 [15166626.001]
  • [Cites] Med Pediatr Oncol. 1995 Feb;24(2):104-8 [7990757.001]
  • [Cites] Cancer Res. 1995 Jul 1;55(13):2853-7 [7796412.001]
  • [Cites] Cancer Res. 1996 Sep 1;56(17):3898-901 [8752155.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4838-48 [9354447.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Feb 24;255(3):774-7 [10049786.001]
  • [Cites] Clin Cancer Res. 1999 Jul;5(7):1786-92 [10430083.001]
  • [Cites] Pharmacol Ther. 1999 May-Jun;82(2-3):241-50 [10454201.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):795-805 [15701870.001]
  • [Cites] Oncologist. 2005 Aug;10(7):508-17 [16079318.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):5892-9 [16043829.001]
  • [Cites] BMC Cancer. 2005;5:131 [16219105.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):67-78 [16443950.001]
  • [Cites] Drug Metab Dispos. 2006 Mar;34(3):420-6 [16381666.001]
  • [Cites] Clin Pharmacol Ther. 2006 Aug;80(2):136-45 [16890575.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5259-64 [17114659.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):69-82 [17222791.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1228-38 [17283159.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] Clin Cancer Res. 2007 Jul 1;13(13):3913-21 [17606725.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):998-1007 [10741727.001]
  • (PMID = 18794549.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCATS NIH HHS / TR / UL1 TR000005; United States / NCI NIH HHS / CA / CA97452; United States / NCI NIH HHS / CA / P30 CA021765
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Quinazolines; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ PMC2652086
  •  go-up   go-down


22. Liu Y, Liu M, Ren P: [Drug delivery of CPC/cisplatin complex in vitro and its ability to repair bone defect and eliminate tumor in vivo]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 Oct;34(10):991-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Drug delivery of CPC/cisplatin complex in vitro and its ability to repair bone defect and eliminate tumor in vivo].
  • METHODS: Mixed-molding method was used to obtain cisplatin/calcium phosphate cement complex at 0, 0.1%, 0.2%, and 0.4% mass ratio.
  • Drug concentration was determined by atomic absorption spectrophotometry.
  • Bone defect of rabbits and osteosarcoma of rats were prepared.
  • RESULTS: CPC containing 0.1% approximately 0.2% cisplatin not only repaired the bone defect in rabbits but also eliminated osteosarcoma in rats.
  • [MeSH-major] Bone Cements / chemistry. Bone Neoplasms / surgery. Bone Regeneration / drug effects. Calcium Phosphates / therapeutic use. Cisplatin / pharmacokinetics
  • [MeSH-minor] Animals. Biocompatible Materials. Bone Substitutes / therapeutic use. Delayed-Action Preparations. Female. Femoral Fractures / surgery. Male. Mice. Mice, Nude. Osteosarcoma / drug therapy. Osteosarcoma / surgery. Rabbits. Random Allocation. Rats. Rats, Sprague-Dawley

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19893250.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biocompatible Materials; 0 / Bone Cements; 0 / Bone Substitutes; 0 / Calcium Phosphates; 0 / Delayed-Action Preparations; 701EKV9RMN / calcium phosphate, monobasic, anhydrous; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


23. Wang H, Nan L, Yu D, Agrawal S, Zhang R: Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms. Clin Cancer Res; 2001 Nov;7(11):3613-24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms.
  • The mouse double minute 2 (MDM2) oncogene has been suggested as a target for cancer therapy.
  • It is amplified or overexpressed in many human cancers, including breast cancer, and MDM2 levels are associated with poor prognosis of several human cancers, including breast cancer, ovarian cancer, osteosarcoma, and lymphoma.
  • In the present study, we investigated the functions of MDM2 oncogene in the growth of breast cancer and the potential value of MDM2 as a drug target for cancer therapy by inhibiting MDM2 expression with a specific antisense antihuman-MDM2 oligonucleotide (oligo).
  • The selected antisense mixed-backbone oligo was evaluated for its in vitro and in vivo antitumor activity in human breast cancer models: MCF-7 cell line containing wild-type p53 and MDA-MB-468 cell line containing mutant p53.
  • In both models, in vivo synergistically or additive therapeutic effects of MDM2 inhibition and the clinically used cancer chemotherapeutic agents irinotecan, 5-fluorouracil, and paclitaxel (Taxol) were observed.
  • This study should provide a basis for future development of anti-MDM2 ASs as cancer therapeutic agents used alone or in combination with conventional chemotherapeutics.
  • [MeSH-major] Breast Neoplasms / drug therapy. Camptothecin / analogs & derivatives. DNA, Antisense / therapeutic use. Nuclear Proteins. Proto-Oncogene Proteins / genetics
  • [MeSH-minor] Animals. Antineoplastic Agents / therapeutic use. Blotting, Western. Cyclin-Dependent Kinase Inhibitor p21. Cyclins / drug effects. Cyclins / metabolism. Dose-Response Relationship, Drug. Doxorubicin / therapeutic use. Drug Synergism. Drug Therapy, Combination. Female. Fluorouracil / therapeutic use. Humans. Mice. Mice, Nude. Mutation. Neoplasm Transplantation. Proto-Oncogene Proteins c-mdm2. Time Factors. Tumor Cells, Cultured. Tumor Suppressor Protein p53 / drug effects. Tumor Suppressor Protein p53 / metabolism. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11705884.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA 80698
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CDKN1A protein, human; 0 / Cdkn1a protein, mouse; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Cyclins; 0 / DNA, Antisense; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins; 0 / Tumor Suppressor Protein p53; 67656-30-8 / 10-hydroxycamptothecin; 80168379AG / Doxorubicin; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Mdm2 protein, mouse; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


24. Egwari LO, Nwokoye NN, Obisesan B, Coker AO, Nwaokorie FO, Savage KO: Bacteriological and clinical evaluation of twelve cases of post-surgical sepsis of odontogenic tumours at a referral centre. East Afr Med J; 2008 Jun;85(6):269-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SUBJECTS: Twelve patients with odontogenic tumours that developed sepsis postoperatively.
  • INTERVENTION: Adequate review of patient's medical history, bacteriological investigations and antibiotic therapy.
  • MAIN OUTCOME MEASURES: Bacteriological and clinical cure following antibiotic therapy based on susceptibility test results.
  • Sepsis developed in the non-compliance group much earlier than in the group that complied (p<0.001).
  • Mixed aerobic and anaerobic aetiology occurred more in osteosarcoma and fibrosarcoma.
  • Clostridium perfringens was isolated from a case of osteosarcoma with necrotic tissues.
  • Over 92% of the streptococci were sensitive to the beta-Lactams contrast low susceptibility with S. aureus and K. pneumoniae.
  • [MeSH-major] Odontogenic Tumors / surgery. Patient Compliance. Postoperative Complications. Sepsis / drug therapy. Sepsis / microbiology
  • [MeSH-minor] Anti-Bacterial Agents / pharmacology. Anti-Bacterial Agents / therapeutic use. Bacteria / drug effects. Bacteria / isolation & purification. Drug Resistance, Bacterial. Humans. Nigeria / epidemiology. Prospective Studies. Referral and Consultation

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Sepsis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18817023.001).
  • [ISSN] 0012-835X
  • [Journal-full-title] East African medical journal
  • [ISO-abbreviation] East Afr Med J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Kenya
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


25. Leu KM, Ostruszka LJ, Shewach D, Zalupski M, Sondak V, Biermann JS, Lee JS, Couwlier C, Palazzolo K, Baker LH: Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol; 2004 May 1;22(9):1706-12
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma.
  • The objective of this report is to describe experience with this combination in a variety of histologic subtypes of sarcoma.
  • Additionally, cell-culture studies were performed to assess the effect of the sequence of drug administration on colony formation.
  • Cell culture studies using the SAOS-2 osteosarcoma cell line and MCF-7 breast cancer cell line were also performed.
  • Responses occurred in uterine, extremity, and retroperitoneal leiomyosarcoma, osteosarcomas, angiosarcomas, malignant fibrous histiocytomas, malignant peripheral-nerve sheath tumors, and Ewing's sarcoma.
  • In the cell culture studies, gemcitabine followed by docetaxel provided synergy.
  • In contrast, the administration of drugs simultaneously resulted in antagonism, and docetaxel followed by gemcitabine provided mixed results.
  • A multicenter, randomized clinical trial in soft tissue sarcoma comparing gemcitabine alone with this combination, is ongoing.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Deoxycytidine / analogs & derivatives. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy. Taxoids / therapeutic use
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Drug Interactions. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15117993.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


26. Burnett BP, Jia Q, Zhao Y, Levy RM: A medicinal extract of Scutellaria baicalensis and Acacia catechu acts as a dual inhibitor of cyclooxygenase and 5-lipoxygenase to reduce inflammation. J Med Food; 2007 Sep;10(3):442-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A mixed extract containing two naturally occurring flavonoids, baicalin from Scutellaria baicalensis and catechin from Acacia catechu, was tested for cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) inhibition via enzyme, cellular, and in vivo models.
  • The 50% inhibitory concentration for inhibition of both ovine COX-1 and COX-2 peroxidase enzyme activities was 15 microg/mL, while the mixed extract showed a value for potato 5-LOX enzyme activity of 25 microg/mL.
  • Prostaglandin E2 generation was inhibited by the mixed extract in human osteosarcoma cells expressing COX-2, while leukotriene production was inhibited in both human cell lines, immortalized THP-1 monocyte and HT-29 colorectal adenocarcinoma.
  • When arachidonic acid was injected directly into the intra-articular space of mouse ankle joints, the mixed extract abated the swelling and restored function in a rotary drum walking model.
  • [MeSH-major] Acacia / chemistry. Cyclooxygenase Inhibitors / administration & dosage. Inflammation / drug therapy. Lipoxygenase Inhibitors. Plant Extracts / administration & dosage. Scutellaria baicalensis / chemistry
  • [MeSH-minor] Animals. Anti-Inflammatory Agents / administration & dosage. Catechin / administration & dosage. Cell Line, Transformed. Cell Line, Tumor. Cyclooxygenase 1. Cyclooxygenase 2. Dinoprostone / metabolism. Enzyme Inhibitors / administration & dosage. Flavonoids / administration & dosage. HT29 Cells. Humans. Male. Mice. Mice, Inbred ICR. Monocytes. Osteosarcoma. Sheep

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17887937.001).
  • [ISSN] 1096-620X
  • [Journal-full-title] Journal of medicinal food
  • [ISO-abbreviation] J Med Food
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Cyclooxygenase Inhibitors; 0 / Enzyme Inhibitors; 0 / Flavonoids; 0 / Lipoxygenase Inhibitors; 0 / Plant Extracts; 347Q89U4M5 / baicalin; 8R1V1STN48 / Catechin; EC 1.14.99.1 / Cyclooxygenase 1; EC 1.14.99.1 / Cyclooxygenase 2; K7Q1JQR04M / Dinoprostone
  •  go-up   go-down


27. Burnei G, Burnei C, Hodorogea D, Gavriliu S, Georgescu I, Vlad C: Osteoarticular reconstructive surgery in malignant bone tumors: the importance of external fixators. J Med Life; 2008 Jul-Sep;1(3):295-306
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patients with malignant bone tumors (table 1.) were studied by sex, tumor type, location, age at the moment of diagnosis, age at the moment of the last evaluation, type of surgery, external fixator implanted, complications, results and survival period.
  • We also considered for each patient the extent of the tumor to diaphysis, soft tissue involvement, involvement of physis and epiphyseal invasion, articular extent, vessels and nerves invasion, presence of metastases and local skin invasion.
  • We used monoplanar or circular fixators, in adjustable or mixed mountings.
  • The conservative treatment is preferred to the amputation, which is being used in very few cases.
  • The development of reconstructive bone surgery is sustained by the possibility to delineate the tumor by diagnosis based on imaging and by the possibility to use modern preoperative and postoperative chemotherapy and radiotherapy.
  • Since then the same treatment was preferred also in malignant bone tumors, because the relapse appeared as frequent as in cases with amputation but the physical and psychological comfort made the patients to accept it readily.
  • The goal of malignant bone tumors treatment is to save the life of the patient, to preserve the affected limb, to maintain the length and function of the limb.
  • Oncologic surgery consists of "en bloc" tumor resection followed by bone reconstruction or modular prosthetic replacement.
  • [MeSH-major] Bone Neoplasms / surgery. Chondrosarcoma / surgery. External Fixators. Giant Cell Tumor of Bone / surgery. Osteosarcoma / surgery
  • [MeSH-minor] Adolescent. Adult. Fatal Outcome. Female. Femur / surgery. Humans. Humerus / surgery. Male. Reconstructive Surgical Procedures / methods. Retrospective Studies. Sarcoma, Ewing / surgery. Tibia / surgery. Transplantation, Autologous. Transplantation, Homologous. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int Orthop. 1987;11(1):35-41 [3549587.001]
  • [Cites] Clin Orthop Relat Res. 2000 Apr;(373):51-61 [10810462.001]
  • [Cites] Rev Chir Orthop Reparatrice Appar Mot. 1985;71(7):435-50 [3911313.001]
  • [Cites] Cancer. 1984 Jun 15;53(12):2579-84 [6372980.001]
  • [Cites] J Bone Joint Surg Br. 1995 Jul;77(4):608-14 [7615607.001]
  • [Cites] Ital J Orthop Traumatol. 1975 Apr;1(1):5-22 [1067250.001]
  • [Cites] J Bone Joint Surg Am. 1988 Apr;70(4):507-16 [3281952.001]
  • [Cites] J Bone Joint Surg Br. 1997 Jul;79(4):558-61 [9250738.001]
  • [Cites] J Bone Joint Surg Am. 1990 Mar;72(3):334-45 [2135632.001]
  • [Cites] Clin Orthop Relat Res. 2001 Sep;(390):212-20 [11550868.001]
  • [Cites] Clin Orthop Relat Res. 1991 Sep;(270):181-96 [1884538.001]
  • [Cites] Int Orthop. 1998;22(1):27-31 [9549578.001]
  • [Cites] J Clin Oncol. 1985 Oct;3(10):1393-9 [4045528.001]
  • [Cites] Int Orthop. 1988;12(1):21-9 [3372098.001]
  • [Cites] Clin Orthop Relat Res. 1986 Mar;(204):9-24 [3456859.001]
  • [Cites] J Bone Joint Surg Am. 1978 Jan;60(1):31-40 [415064.001]
  • [Cites] Acta Orthop Scand. 1989 Apr;60(2):143-53 [2658466.001]
  • [Cites] Int Orthop. 1998;22(5):330-4 [9914940.001]
  • [Cites] Clin Orthop Relat Res. 1993 Jan;(286):241-6 [8425352.001]
  • (PMID = 20108507.001).
  • [ISSN] 1844-122X
  • [Journal-full-title] Journal of medicine and life
  • [ISO-abbreviation] J Med Life
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


28. Yura S, Terahata S, Ohga N, Yamashita T: A case of carcinosarcoma arising in the submandibular gland. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Jun;103(6):820-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Total excision of the left submandibular gland with radical neck dissection was performed under a diagnosis of a submandibular tumor, probably a malignant mixed tumor.
  • The epithelial component was composed of squamous cell carcinoma, undifferentiated carcinoma, and adenocarcinoma.
  • The nonepithelial component was composed of chondrosarcoma, osteosarcoma, spindle cell sarcoma, rhabdomyosarcoma, and liposarcoma.
  • In view of the expected aggressive nature of the tumor, the patient was treated with postoperative radiotherapy of 60 Gy total, in 30 daily fractions of 2 Gy, and chemotherapy.
  • He currently remains well and free of disease 24 months after treatment.
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Postoperative Care. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17531942.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement